Related Experiment Video
Updated: Jun 14, 2026
06:44
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Boric acid as a protector against paclitaxel genotoxicity
Hasan Turkez1, Abdulgani Tatar, Ahmet Hacimuftuoglu
1Department of Biology, Faculty of Science, Ataturk University, Erzurum, Turkey.
Acta Biochimica Polonica
|March 20, 2010
Summary
Boric acid (BA) may protect healthy human cells from the genotoxic effects of the chemotherapy drug Paclitaxel (PAC). This study found BA reduced PAC-induced DNA damage in human lymphocytes, suggesting a potential protective role.
Area of Science:
- Biochemistry
- Genetics
- Toxicology
Background:
- Paclitaxel (PAC) is a crucial chemotherapy agent for breast, ovarian, and lung cancers.
- Limited data exists on Paclitaxel's genotoxicity in healthy human cells.
- Boron's biological effects are known, but its interaction with Paclitaxel is unexplored.
Purpose of the Study:
- To investigate if boric acid (BA) can mitigate Paclitaxel-induced genotoxicity.
- To assess the protective potential of boric acid against Paclitaxel's DNA-damaging effects on human cells.
Main Methods:
- Human blood cultures were treated with Paclitaxel (10 or 20 microg/l) and boric acid (2.5 or 5 mg/l).
- Genotoxicity was evaluated using sister chromatid exchange (SCE) and micronucleus (MN) tests.
- Nuclear division index (NDI) was analyzed in peripheral lymphocytes.
Main Results:
- Paclitaxel significantly increased SCE and MN frequencies, indicating genotoxicity (P<0.05).
- Paclitaxel treatment decreased the nuclear division index in lymphocytes.
- Boric acid alone showed no cytotoxic or genotoxic effects at tested concentrations.
- Boric acid addition reduced Paclitaxel-induced genotoxicity and cytotoxicity.
Conclusions:
- Boric acid demonstrates a protective effect against Paclitaxel genotoxicity in human lymphocytes.
- This is the first study suggesting boric acid's potential to prevent Paclitaxel-induced DNA damage.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...